NCT01515319 - Safety and Pharmacokinetic Study of Y242 in Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Obesity

Interventions

DRUG

Y242

Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

DRUG

0.9% saline

Identical volume to that of Y242

Trial Locations (1)

HA1 3UJ

PAREXEL Early Phase Clinical Unit, London